[go: up one dir, main page]

AU2001244726A1 - Oxazole derivatives and their uses as tyrosine kinase inhibitors - Google Patents

Oxazole derivatives and their uses as tyrosine kinase inhibitors

Info

Publication number
AU2001244726A1
AU2001244726A1 AU2001244726A AU4472601A AU2001244726A1 AU 2001244726 A1 AU2001244726 A1 AU 2001244726A1 AU 2001244726 A AU2001244726 A AU 2001244726A AU 4472601 A AU4472601 A AU 4472601A AU 2001244726 A1 AU2001244726 A1 AU 2001244726A1
Authority
AU
Australia
Prior art keywords
compound
salt
drug
cancer
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001244726A
Other languages
English (en)
Inventor
Takenori Hitaka
Etsuya Matsutani
Akihiro Tasaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AU2001244726A1 publication Critical patent/AU2001244726A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2001244726A 2000-04-07 2001-04-05 Oxazole derivatives and their uses as tyrosine kinase inhibitors Abandoned AU2001244726A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-106836 2000-04-07
JP2000106836 2000-04-07
PCT/JP2001/002937 WO2001077107A1 (en) 2000-04-07 2001-04-05 Oxazole derivatives and their uses as tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
AU2001244726A1 true AU2001244726A1 (en) 2001-10-23

Family

ID=18619943

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001244726A Abandoned AU2001244726A1 (en) 2000-04-07 2001-04-05 Oxazole derivatives and their uses as tyrosine kinase inhibitors

Country Status (19)

Country Link
US (2) US6716863B2 (pt)
EP (1) EP1268473A1 (pt)
KR (1) KR20020028865A (pt)
CN (1) CN1444582A (pt)
AU (1) AU2001244726A1 (pt)
BR (1) BR0109851A (pt)
CA (1) CA2404760A1 (pt)
CO (1) CO5261589A1 (pt)
CZ (1) CZ20023264A3 (pt)
EE (1) EE200200576A (pt)
HU (1) HUP0300434A3 (pt)
IL (1) IL152115A0 (pt)
MX (1) MXPA02009621A (pt)
NO (1) NO20024742L (pt)
OA (1) OA12244A (pt)
PE (1) PE20011178A1 (pt)
PL (1) PL365787A1 (pt)
SK (1) SK14132002A3 (pt)
WO (1) WO2001077107A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114217025A (zh) * 2021-12-17 2022-03-22 航天科工智慧产业发展有限公司 评估空气质量浓度预测中气象数据对其影响的分析方法

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6004999A (en) * 1998-10-08 2000-04-26 Takeda Chemical Industries Ltd. Agents for retarding change of hormone-dependent cancer into hormone-independentcancer
KR20050063747A (ko) * 2000-07-19 2005-06-28 다케다 야쿠힌 고교 가부시키가이샤 1-치환-1,2,3-트리아졸 유도체, 그 중간체, 및 이들의제조 방법
US20040235748A1 (en) * 2001-04-25 2004-11-25 Yasutaka Igari Agents for preventing postoperative recurrence of premenopausal breast cancer
US20040116330A1 (en) * 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
US20040138160A1 (en) * 2001-04-27 2004-07-15 Kenichiro Naito Preventive/therapeutic method for cancer
CA2458452C (en) * 2001-08-10 2011-04-19 Takeda Chemical Industries, Ltd. Gnrh agonist combination drugs
WO2003031442A1 (fr) * 2001-10-05 2003-04-17 Takeda Chemical Industries, Ltd. Composes heterocycliques, derives oxazole, procede permettant de les presenter et leur utilisation
US7812044B2 (en) 2001-11-13 2010-10-12 Takeda Pharmaceutical Company Limited Anticancer agents
WO2003045929A1 (fr) * 2001-11-26 2003-06-05 Takeda Chemical Industries, Ltd. Derive bicyclique, procede de production de ce derive et utilisation correspondante
WO2003059907A1 (fr) * 2002-01-17 2003-07-24 Takeda Chemical Industries, Ltd. Composes heterocycliques azotes : procede de preparation et d'utilisation
IL164799A0 (en) 2002-04-25 2005-12-18 Univ Connecticut Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
ME00076B (me) * 2002-12-16 2011-02-10 Kissei Pharmaceutical Lijek u čvrstom obliku za oralnu primjenu
TW200505913A (en) * 2003-03-28 2005-02-16 Hoffmann La Roche Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
AR044098A1 (es) * 2003-04-30 2005-08-24 Hoffmann La Roche Derivados de anilina, su elaboracion, composiciones farmaceuticas y su uso para elaborar medicamentos para el tratamiento del cancer
US7247649B2 (en) 2003-08-13 2007-07-24 Hoffmann-La Roche Inc. Oxazoles, their manufacture and use as pharmaceutical agents
US7259262B2 (en) 2003-10-24 2007-08-21 Hoffmann-La Roche Inc. Arylazole derivatives, their manufacture and use as pharmaceutical agents
US20050186275A1 (en) * 2004-02-23 2005-08-25 Standard Chem. & Pharm. Co. Ltd. Sustained release tamsulosin formulations
TW200531688A (en) 2004-03-05 2005-10-01 Hoffmann La Roche Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
TW200612914A (en) * 2004-03-05 2006-05-01 Hoffmann La Roche Novel oxidized thioether derivatives, their manufacture and use as pharmaceutical agents
TW200533346A (en) 2004-03-18 2005-10-16 Hoffmann La Roche Novel ether derivatives, their manufacture and use as pharmaceutical agents
WO2005097777A1 (en) * 2004-04-02 2005-10-20 F. Hoffmann-La-Roche Ag New process for the preparation of diazine derivatives
US7163953B2 (en) * 2004-05-25 2007-01-16 Hoffmann-La Roche Inc. Benzylether derivatives
US7005526B2 (en) * 2004-05-25 2006-02-28 Hoffmann-La Roche Inc. Thioether derivatives
US7618769B2 (en) * 2004-06-07 2009-11-17 Applied Materials, Inc. Textured chamber surface
US7288557B2 (en) 2004-09-21 2007-10-30 Hoffmann-La Roche Inc. Triazole derivatives
TW200616951A (en) * 2004-09-22 2006-06-01 Hoffmann La Roche Indole derivatives, their manufacture and use as pharmaceutial agents
US20060069095A1 (en) * 2004-09-24 2006-03-30 Thomas Hofmeister Azole derivatives
US20060116407A1 (en) * 2004-11-22 2006-06-01 Birgit Bossenmaier Amide derivatives
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
TW200738680A (en) 2005-08-04 2007-10-16 Hoffmann La Roche Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents
EP1915370A1 (en) * 2005-08-08 2008-04-30 F.Hoffmann-La Roche Ag Pyrazole derivatives, their manufacture and their use as pharmaceutical agents
JP2009509998A (ja) * 2005-09-30 2009-03-12 エフ．ホフマン−ラ ロシュ アーゲー ジアジンアゾール誘導体、それらの製造及び薬剤としての使用
WO2008034579A1 (en) * 2006-09-20 2008-03-27 F. Hoffmann-La Roche Ag 2-heterocyclyl-5-phenoxymethylpyridine derivatives as anticancer agents
JPWO2008072634A1 (ja) 2006-12-12 2010-04-02 武田薬品工業株式会社 縮合複素環化合物
US9101617B2 (en) 2007-04-20 2015-08-11 Daido Chemical Corporation Base for dry solid dispersion, solid dispersion containing the base, and composition containing the dispersion
AR070874A1 (es) 2008-03-12 2010-05-12 Takeda Pharmaceutical Compuesto heterociclico fusionado, una composicion farmaceutica que lo comprende y su uso en el tratamiento del cancer.
AR073679A1 (es) * 2008-09-26 2010-11-24 Takeda Pharmaceutical Prevencion y tratamiento de cancer con la no expresion de lkb1 supresion o mutacion, composicion farmaceutica. usos
AR073680A1 (es) * 2008-09-26 2010-11-24 Takeda Pharmaceutical Prevencion y tratamiento de cancer con la mutacion del gen ras. composicion farmaceutica. uso.
WO2011039952A1 (ja) 2009-09-30 2011-04-07 株式会社サンギ 難溶性物質の水溶解性改善方法
JP5705206B2 (ja) 2010-02-26 2015-04-22 日新化成株式会社 硬カプセルおよびその製造方法
US8993634B2 (en) 2010-06-02 2015-03-31 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to Her2/neu receptor complex
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
JP5909796B2 (ja) 2012-03-02 2016-04-27 株式会社サンギ 難溶性物質の水溶解性改善方法
US9364438B2 (en) 2012-09-26 2016-06-14 Takeda Pharmaceutical Company Limited Process for producing solid particles
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
EP3795609B1 (en) 2015-07-01 2024-04-03 California Institute of Technology Cationic mucic acid polymer-based delivery systems
EP3238711B1 (en) 2016-04-26 2023-07-12 Mitsubishi Chemical Corporation Base for solid dispersion, production method for solid dispersion using same, and solid dispersion
CA2995617A1 (en) * 2017-11-03 2019-05-03 Universite De Montreal Heterocyclic mitochondrial activity inhibitors and uses thereof
US20190381188A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05506857A (ja) 1990-04-16 1993-10-07 ローヌ―プーラン　ローラー　インターナショナル　（ホウルディングス）インコーポレイテッド Ｅｇｆレセプタチロシンキナーゼを阻害するスチリル―置換単環式および二環式複素アリール化合物
AU3461697A (en) * 1996-07-19 1998-02-10 Takeda Chemical Industries Ltd. Heterocyclic compounds, their production and use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114217025A (zh) * 2021-12-17 2022-03-22 航天科工智慧产业发展有限公司 评估空气质量浓度预测中气象数据对其影响的分析方法
CN114217025B (zh) * 2021-12-17 2024-01-23 哈尔滨工业大学 评估空气质量浓度预测中气象数据对其影响的分析方法

Also Published As

Publication number Publication date
CN1444582A (zh) 2003-09-24
NO20024742L (no) 2002-11-25
CA2404760A1 (en) 2001-10-18
EP1268473A1 (en) 2003-01-02
HUP0300434A3 (en) 2004-11-29
KR20020028865A (ko) 2002-04-17
WO2001077107B1 (en) 2001-12-20
US6716863B2 (en) 2004-04-06
PE20011178A1 (es) 2001-11-19
PL365787A1 (en) 2005-01-10
SK14132002A3 (sk) 2003-04-01
EE200200576A (et) 2004-06-15
OA12244A (en) 2006-05-10
CO5261589A1 (es) 2003-03-31
WO2001077107A8 (en) 2003-02-13
US20040024035A1 (en) 2004-02-05
BR0109851A (pt) 2003-06-03
NO20024742D0 (no) 2002-10-02
WO2001077107A1 (en) 2001-10-18
MXPA02009621A (es) 2003-05-14
IL152115A0 (en) 2003-05-29
HUP0300434A2 (hu) 2003-06-28
US20020173526A1 (en) 2002-11-21
CZ20023264A3 (cs) 2003-02-12

Similar Documents

Publication Publication Date Title
US6716863B2 (en) Heterocyclic compounds their production and use
US6984653B2 (en) Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof
RU2418793C2 (ru) Соединение оксазола и фармацевтическая композиция
TWI419897B (zh) 磺醯胺衍生物
CN1075073C (zh) 杂芳环取代的苯基噁唑烷酮抗菌剂
AU2008205169B2 (en) Imidazole derivatives as kinesin spindle protein inhibitors (Eg-5)
EP1987025B1 (en) Benzoxazinone and benzoxazepinone oxazolidinones as antibacterial agents
JP2014525932A (ja) リゾホスファチド酸レセプターアンタゴニスト
UA111754C2 (uk) Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
EA007490B1 (ru) N-арил-2-оксазолидинон-5-карбоксамиды, их производные и их применение в качестве антибактериальных средств
JP4986927B2 (ja) 医薬
US6743924B2 (en) Method for producing 1-substituted-1,2,3-triazole derivative
JP3273777B2 (ja) 複素環化合物、その製造法および用途
US7498353B2 (en) Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
JP2002069070A (ja) 複素環化合物、その製造法および用途
JP2004161660A (ja) リウマチ予防・治療剤
TW200813007A (en) Substituted pyrrole derivatives
JP2003176287A (ja) 複素環化合物オキサゾール誘導体、その製造法および用途
EP4313973A1 (en) Novel potassium channel inhibitors
JP2005035944A (ja) スチレン誘導体、その製造法および用途
JP2005035935A (ja) オキサゾール化合物およびその用途